Author

A. Trautmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:flow cytometry· 1

Frequent Co-Authors

E. Donnadieu· 3 shared L. Vimeux· 3 shared N. Bercovici· 3 shared G. Bismuth· 2 shared V. Feuillet· 2 shared A. Kaiser· 1 shared A. Kinkhabwala· 1 shared A. Lupo· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

E. Donnadieu

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CAR T cell entry into tumor islets is a two-step process dependent on IFNγ and ICAM-1

C. Kantari-Mimoun, S. Barrin, S. Haghiri, C. Gervais, J. Mittelstaet, N. Mockel-Tenbrinck, A. Kinkhabwala, D. Damotte, A. Lupo, M. Sibony, M. Alifano, L. Vimeux, E. Dondi, N. Bercovici, A. Trautmann, , E. Donnadieu

This study shows CAR T cell entry into tumor islets occurs in two steps, requiring IFNγ and ICAM-1 for effective infiltration.

bioRxiv · May 27, 2020Immunology

TGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors

M. V. V. Guerin, F. Regnier, V. Feuillet, L. Vimeux, J. M. Weiss, G. Bismuth, G. Altan-Bonnet, T. Guilbert, M. Thoreau, V. Finisguerra, E. Donnadieu, A. Trautmann, N. Bercovici

This study shows that TGFβ inhibits IFNα/β production and tumor rejection in spontaneous mammary tumors, and blocking TGFβ enhances DMXAA-induced tumor regression.

bioRxiv · Jul 9, 2019Cancer Biology

Blockade of β-adrenergic receptor signaling improves cancer vaccine efficacy through its effect on naive CD8+ T-cell priming

C. Daher, L. Vimeux, R. Stoeva, E. Peranzoni, G. Bismuth, E. Donnadieu, N. Bercovici, A. Trautmann, V. Feuillet

This study shows that blocking β-adrenergic receptor signaling enhances cancer vaccine efficacy by improving naive CD8+ T-cell priming, without affecting tumor-infiltrating CD8+ T-cell reactivity.

bioRxiv · Dec 16, 2018 · PreprintImmunology